Eesti - eesti - Ravimiamet

stada arzneimittel ag - lisdeksamfetamiindimesülaat - kõvakapsel - 20mg 100tk; 20mg 30tk

Eesti - eesti - Ravimiamet

stada arzneimittel ag - lisdeksamfetamiindimesülaat - kõvakapsel - 30mg 100tk

Eesti - eesti - Ravimiamet

stada arzneimittel ag - lisdeksamfetamiindimesülaat - kõvakapsel - 40mg 100tk

Eesti - eesti - Ravimiamet

stada arzneimittel ag - lisdeksamfetamiindimesülaat - kõvakapsel - 60mg 30tk; 60mg 100tk

Eesti - eesti - Ravimiamet

stada arzneimittel ag - lisdeksamfetamiindimesülaat - kõvakapsel - 50mg 30tk; 50mg 100tk

Eesti - eesti - Ravimiamet

stada arzneimittel ag - lisdeksamfetamiindimesülaat - kõvakapsel - 70mg 100tk; 70mg 30tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

amarin pharmaceuticals ireland limited - icosapent ethyl - düslipideemiad - lipiidi modifitseerivad ained - indicated to reduce cardiovascular risk as an adjunct to statin therapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

mylan ireland limited - fingolimod vesinikkloriid - sclerosis multiplex, relapsing-remitting - immunosupressandid - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 ja 5. 1)orpatients kiiresti arenev raske relapsing remitting sclerosis multiplex määratud 2 või enam puuet ägenemiste ühe aasta, ja on 1 või enam gadoliinium suurendada kahjustused aju mri või olulist kasvu, t2 kahjustus koormus võrreldes varasema hiljutise mrt.

Euroopa Liit - eesti - EMA (European Medicines Agency)

mylan ireland limited - fingolimod vesinikkloriid - sclerosis multiplex, relapsing-remitting - immunosupressandid - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 ja 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Euroopa Liit - eesti - EMA (European Medicines Agency)

pfizer europe ma eeig - somatrogon - growth and development - hÜpofÜÜsi ja hÜpotaalamuse hormoonid ja nende analoogid - indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone.